<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="319">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04357808</url>
  </required_header>
  <id_info>
    <org_study_id>SARCOVID</org_study_id>
    <secondary_id>2020-001634-36</secondary_id>
    <nct_id>NCT04357808</nct_id>
  </id_info>
  <brief_title>Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)</brief_title>
  <acronym>SARCOVID</acronym>
  <official_title>Randomized Open Pilot Study to Evaluate the Efficacy of Subcutaneous Sarilumab in Patients With Moderate-severe COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria del Rosario Garcia de Vicuña Pinedo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Investigación Sanitaria Hospital Universitario de la Princesa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The global health emergency created by the rapid spread of the SARS-CoV-2 coronavirus has
      pushed healthcare services to face unprecedent challenges to properly manage COVID-19 severe
      and critical manifestations affecting a wide population in a short period of time. Clinicians
      are committed to do their best with a great uncertainty in this evolving crisis. Off label
      use of plenty of drugs has arisen the need for clinical trials to demonstrate their true role
      in the therapy. Based in unpublished experiences in China, Italy and Spain, intravenous IL-6
      receptor inhibitors are now being tested in several trials but no data on subcutaneous
      formulations are available yet. Sarilumab is a human monoclonal antibody that binds
      membrane-bound and soluble IL-6 receptors to inhibit IL-6 signalling, licensed in a
      subcutaneous route administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SARCOVID is an investigator-initiated monocentric randomised proof of concept study that aims
      to evaluate the efficacy and safety of a single dose of sarilumab, in subcutaneous
      administration, in hospitalised patients with moderate to early severe COVID-19 infection,
      compared to the current standard of care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised, open-label, single-center, comparative trial of sarilumab plus standard of care vs. standard of care in a 2:1 ratio.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation</measure>
    <time_frame>7 days from enrolment</time_frame>
    <description>Score ranges 1-7
Death;
Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO);
Hospitalized, requiring non-invasive ventilation or high flow oxygen devices;
Hospitalized, requiring supplemental oxygen;
Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)
Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care
Not hospitalized</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of hospitalisation (days)</measure>
    <time_frame>30 days from enrolment</time_frame>
    <description>Days from the date of enrolment to the date of discharge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>30 days from enrolment</time_frame>
    <description>Number of deaths</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to become afebrile (days)</measure>
    <time_frame>30 days from enrolment</time_frame>
    <description>Time to become afebrile for a minimum period of 48 hours, without antipyretics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to non-invasive mechanical ventilation (days)</measure>
    <time_frame>30 days from enrolment</time_frame>
    <description>Days from enrolment to non-invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to invasive mechanical ventilation (days)</measure>
    <time_frame>30 days from enrolment</time_frame>
    <description>Days from enrolment to invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to independence from supplementary oxygen therapy (days)</measure>
    <time_frame>30 days from enrolment</time_frame>
    <description>Days from enrolment to supplementary oxygen therapy withdrawal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in clinical status assessment using the 7-point ordinal scale at day 14 after randomisation</measure>
    <time_frame>14 days from enrolment</time_frame>
    <description>Scale ranges 1-7:
Death
Hospitalized, with mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
Hospitalized, with non-invasive mechanical ventilation, a mask with a reservoir or oxygen with high flow nasal goggles.
Hospitalized with oxygen supplement
Hospitalized, without oxygen supplement, but in need of continued medical care (related or not with COVID)
Hospitalized, without oxygen supplement and without the need for continued medical care
Not hospitalized</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of serious and non-serious adverse events.</measure>
    <time_frame>30 days after enrolment</time_frame>
    <description>Number of adverse events and number of patients with adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Discontinuation due to adverse reactions</measure>
    <time_frame>30 days after enrolment</time_frame>
    <description>Number of adverse reactions that requires discontinuation of any drug in the study</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Sarilumab plus standard of care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarilumab 200 mg, 2 sc injections in pre-filled syringe or pen, single dose. Treatment with drugs or procedures in routine clinical practice that the clinician responsible for the patient deems necessary is allowed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with drugs or procedures in routine clinical practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarilumab</intervention_name>
    <description>Single dose treatment with sarilumab 2 x 200 mg subcutaneously</description>
    <arm_group_label>Sarilumab plus standard of care</arm_group_label>
    <other_name>Kevzara</other_name>
    <other_name>SAR153191</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standar of care</intervention_name>
    <description>Usual clinical care</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt; 18 years

          -  Laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other validated
             commercial or public health assay

          -  Documented interstitial pneumonia requiring admission and at least two of the
             following:

               1. Fever ≥ 37.8ºC (tympanic)

               2. IL-6 in serum ≥ 25 ng / mL (in the absence of a previous dose of prednisone or
                  equivalent&gt; 1 mg / kg) or PCR&gt; 5mg / dL

               3. Lymphocytes &lt;600 mm3

               4. Ferritin&gt; 300 mcg / L that doubles in 24 hours

               5. Ferritin&gt; 600 mcg / L in the first determination and LDH&gt; 250 U / L

               6. D-dimer (&gt; 1 mg / L)

          -  Informed verbal or administration consent under urgent conditions, documented in the
             electronic medical record.

        Exclusion Criteria:

          -  Patients who require mechanical ventilation at the time of inclusion.

          -  AST / ALT values &gt; 5 folds upper normal limit.

          -  Neutrophil count below 500 cells / mm3

          -  Platelet count below 50,000 cells / mm3

          -  Documented sepsis or high suspicion by pathogens other than COVID-19.

          -  Presence of comorbidities that according to clinical judgment could lead to an
             unfavorable result.

          -  Complicated diverticulitis or intestinal perforation.

          -  Current skin infection (eg, uncontrolled dermopiodermitis).

          -  Immunosuppressive anti-rejection therapy.

          -  Pregnancy or lactation.

          -  Previous treatment with tocilizumab or sarilumab.

          -  Patients participating in some other clinical trial for SARS-CoV-2 infection.

          -  Patients with known hypersensitivity or contraindication to sarilumab or excipients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosario Garcia de Vicuña, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rosario Garcia de Vicuña, MD PhD</last_name>
    <phone>+34 91 5202473</phone>
    <email>mariadelrosario.garcia@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jesús Sanz Sanz, MD PhD</last_name>
    <phone>+34 91 5204014</phone>
    <email>jsanzsanz@salud.madrid.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosario Garcia de Vicuña, MD, PhD</last_name>
      <phone>+34915202438</phone>
      <email>mariadelrosario.garcia@salud.madid.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</investigator_affiliation>
    <investigator_full_name>Maria del Rosario Garcia de Vicuña Pinedo</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>COVID</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>coronavirus infections</keyword>
  <keyword>sarilumab</keyword>
  <keyword>IL-6 receptor inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

